Keywords:
Motixafortide, Motixafortide’s R&D Progress, Mechanism of Action for Motixafortide, drug target for Motixafortide.
Description:
This article summarized the latest R&D progress of Motixafortide, the Mechanism of Action for Motixafortide, and the drug target R&D trends for Motixafortide.
Text:
Motixafortide‘s R&D Progress
Motixafortide is a synthetic peptide drug that targets CXCR4, a receptor involved in various biological processes. It has shown potential therapeutic benefits in multiple therapeutic areas, including neoplasms, hemic and lymphatic diseases, infectious diseases, congenital disorders, respiratory diseases, digestive system disorders, endocrinology and metabolic diseases, other diseases, immune system diseases, and cardiovascular diseases.
The active indications for Motixafortide include multiple myeloma, hematopoietic stem cell transplantation, pancreatic ductal carcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, acute lymphoblastic leukemia, pancreatic cancer, secondary malignant neoplasm of the pancreas, myelodysplastic syndromes, acute myeloid leukemia, stomach cancer, metastatic pancreatic ductal adenocarcinoma, stem cell mobilization, anemia (sickle cell), SARS-CoV-2 acute respiratory disease, respiratory tract infections, and chronic myelogenous leukemia.
Motixafortide was developed by Biokine Therapeutics Ltd., an originator organization in the pharmaceutical industry. It has reached the highest phase of development, which is approved globally. In China, it has reached phase 2 of development.
The drug received its first approval in the United States in September 2023. It is regulated as an orphan drug, indicating that it is intended to treat rare diseases or conditions.
Motixafortide’s synthetic peptide nature and its specific targeting of CXCR4 make it a promising candidate for various diseases and conditions. Its approval in multiple therapeutic areas and its orphan drug status highlight its potential to address unmet medical needs.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for Motixafortide: CXCR4 antagonists
From a biomedical perspective, CXCR4 antagonists are a type of drug that specifically target and block the CXCR4 receptor. CXCR4 is a chemokine receptor found on the surface of cells, particularly immune cells. It plays a crucial role in cell migration and is involved in various physiological processes, including immune response, inflammation, and cancer metastasis.
By acting as antagonists, these drugs bind to the CXCR4 receptor and prevent the binding of its natural ligand, CXCL12. This blockade inhibits the signaling pathway mediated by CXCR4, thereby modulating the functions of immune cells and affecting their migration and activation.
CXCR4 antagonists have shown potential therapeutic applications in various diseases. In cancer, for example, they can be used to inhibit the metastasis of tumor cells by blocking the interaction between CXCR4 and CXCL12, which is essential for cancer cell migration and invasion. Additionally, CXCR4 antagonists have been investigated in the treatment of HIV/AIDS, as the CXCR4 receptor serves as a co-receptor for HIV entry into immune cells.
It is important to note that CXCR4 antagonists are still under development and further research is needed to fully understand their efficacy, safety, and potential side effects in different clinical settings.
Drug Target R&D Trends for Motixafortide
CXCR4 is a chemokine receptor protein that plays a crucial role in various physiological processes in the human body. It is primarily involved in cell migration, immune response, and hematopoiesis. CXCR4 acts as a receptor for the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1). This interaction regulates the movement and homing of immune cells, such as lymphocytes and hematopoietic stem cells, to specific tissues and organs. Additionally, CXCR4 has been implicated in various diseases, including cancer metastasis, HIV infection, and autoimmune disorders. Understanding the role of CXCR4 provides valuable insights for the development of targeted therapies in the pharmaceutical industry.
According to Patsnap Synapse, as of 10 Oct 2023, there are a total of 84 CXCR4 drugs worldwide, from 97 organizations, covering 122 indications, and conducting 297 clinical trials.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In conclusion, Motixafortide is a synthetic peptide drug developed by Biokine Therapeutics Ltd. It targets CXCR4 and has shown potential in treating a wide range of diseases and conditions. With its highest phase of development being approved globally and its first approval in the United States, Motixafortide holds promise for patients suffering from various medical conditions.
